Molecular Targeting Technologies, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2011-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.mtarget.com
Clinical Trials
2
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors
Phase 1
Recruiting
- Conditions
- Neuroendocrine Tumors
- Interventions
- Other: Amino Acid Solution
- First Posted Date
- 2022-07-26
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Molecular Targeting Technologies, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT05475210
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Study of 99mTc-glucarate to Detect Acute Coronary Syndrome in Chest Pain Patients.
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2013-10-24
- Lead Sponsor
- Molecular Targeting Technologies, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT00614354
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Yale University, New Haven, Connecticut, United States
🇺🇸University Hospital Case Medical Center, Cleveland, Ohio, United States
News
No news found